Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
10
×
Tags
biotech
boston blog main
deals
10
×
life sciences
national blog main
clinical trials
boston top stories
boston
national top stories
fda
san francisco blog main
investing
san francisco top stories
sanofi
alnylam pharmaceuticals
new york blog main
new york top stories
roche
startups
abbvie
akouos
alexion pharmaceuticals
allergan
amgen
autoimmune disorders
cancer
crispr
editas medicine
ipo
novartis
rna interference
sickle cell disease
venture capital
alirocumab
allosteric
alzheimer's disease
amag pharmaceuticals
amunix
amyotrophic lateral sclerosis (als)
anirvan ghosh
What
medicines
10
×
drug
research
deal
disease
fda
ipo
new
therapeutics
biotech
cancer
candidate
developing
gene
pact
pharma
pharmaceuticals
plans
potential
roche
targets
team
years
abbvie
acquire
acquisitions
address
adds
affects
ago
agreed
aims
alliance
allosteric
alternative
americans
announced
approach
approval
approved
Language
unset
10
×
Current search:
medicines
×
photo
×
unset
×
deals
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds